A pioneering genetic treatment is saving lives where chemotherapy failed, offering new hope for children and adults with ...

A chemotherapy-free-based regimen of the TKI ponatinib combined with targeted immunotherapy showed significant benefits in ...

At a data cut-off of 37.3 months, EFS improved to 3.4 months for crenolanib, compared with 0.0 months for placebo.

Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of ...

A small group of patients with an otherwise incurable form of T‑cell leukaemia have seen their cancer driven into remission by an innovative form of ...

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when ...

"We just have to keep going.... Because he deserves nothing but the best, nothing but positivity and good vibes and ...

The U.S. Food and Drug Administration has approved an expanded indication for Eli Lilly's Jaypirca (pirtobrutinib), the first and only noncovalent Bruton tyrosine kinase (BTK) inhibitor for adults ...

T therapy has helped previously untreatable for T-cell acute lymphoblastic leukemia patients achieve remission, with 82% ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, ...